CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Venetoclax Obinutuzumab|
|Strength||10 mg, 50 mg and 100 mg|
|Indication||Chronic Lymphocytic Leukemia (CLL)|
|Funding Request||Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible.|
|Pre Noc Submission||Yes|
|NOC Date||April 28, 2020|
|Submission Date||April 17, 2020|
|Submission Deemed Complete||May 7, 2020|
|Stakeholder Input Deadline ‡||May 1, 2020|
|Check-point meeting||June 25, 2020|
|pERC Meeting||October 15, 2020|
|Initial Recommendation Issued||October 29, 2020|
|Feedback Deadline ‡||November 12, 2020|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued||November 17, 2020|
|Notification to Implement Issued||December 2, 2020|
|Therapeutic Area||Obinutuzumab for CLL|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.